このエントリーをはてなブックマークに追加
ID 32998
フルテキストURL
著者
Koizumi, Hiroki Department of Psychiatry, Chiba University Graduate School of Medicine
Hashimoto, Kenji Department of Psychiatry, Chiba University Graduate School of Medicine
Kumakiri, Chikara Department of Psychiatry, Chiba University Graduate School of Medicine
Shimizu, Eiji Department of Psychiatry, Chiba University Graduate School of Medicine
Sekine, Yoshimoto Department of Psychiatry and Neurology, Hamamatsu University School of Medicine
Ozaki, Norio Department of Psychiatry, Fujita Health University School of Medicine
Inada, Toshiya Department of Psychiatry, Nagoya University Graduate School of Medicine
Harano, Mutsuo Department of Neuropsychiatry, Kurume University School of Medicine
Komiyama, Tokutaro National Center Hospital for Mental, Nervous, and Muscular Disorders, National Center of Neurology and Psychiatry
Yamada, Mitsuhiko Karasuyama Hospital, Showa University School of Medicine
Sora, Ichiro Division of Psychobiology, Tohoku University Graduate School of Medicine
Ujike, Hiroshi Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry
Takei, Nori Department of Psychiatry and Neurology, Hamamatsu University School of Medicine
Iyo, Masaomi Department of Psychiatry, Chiba University Graduate School of Medicine
抄録
Several lines of evidence suggest that increased generation of auto-oxidized dopamine (DA) o-quinone is associated with the neurotoxicity of methamphetamine (MAP) in the brain, and that, as a cellular defenses against DA-derived quinines, glutathione S-transferase (GST) detoxifies auto-oxidized DA o-quinone in the brain. Glutathione S-transferase M1 (GSTM1) of the mu-class of GSTs catalyzes reaction between glutathione and catecholamine o-quinones under physiological conditions. This study was undertaken to investigate the role of the GSTM1 gene deletion polymorphism in the neuropathology of MAP abuse. One hundred fifty-seven MAP abusers and 200 healthy comparison subjects were tested for a genetic polymorphism of GSTM1. The difference in the frequency of deletion (D)/nondeletion (N) alleles between the female abusers and female controls was close to statistical significance (P=0.071), although there was no statistical difference (P=0.651) between male abusers and male controls. Furthermore, the number of female abusers with deletion alleles was significantly (P=0.007, odds ratio: 2.77, 95% CI 1.30-5.89) higher than that of male abusers with deletion alleles. These findings suggest that GSTM1 gene deletion may contribute to a vulnerability to MAP abuse in female subjects, but not in male subjects. (C) 2003 Wiley-Liss, Inc.
キーワード
methamphetamine
drug abuse
Glutathione S-transferase
gender difference
備考
Digital Object Identifer:10.1002/ajmg.b.20148
Published with permission from the copyright holder. This is the author's copy, as published in American Journal of Medical Genetics Part B, Neuropsychiatric Genetics, Apr 2004, Volume 126B, Issue 1, Pages 43-45.
Publisher URL:http://dx.doi.org/10.1002/ajmg.b.20148
Direct access to Thomson Web of Science record
Copyright © 2003 Wiley-Liss, Inc. All rights reserved.
発行日
2004-04-01
出版物タイトル
American Journal of Medical Genetics Part B, Neuropsychiatric Genetics
126B巻
1号
出版者
Wiley-Liss, Inc.
開始ページ
43
終了ページ
45
ISSN
0148-7299
NCID
AA11815089
資料タイプ
学術雑誌論文
言語
English
著作権者
Wiley-Liss, Inc.
論文のバージョン
author
査読
有り
DOI
PubMed ID
Web of Sience KeyUT
Submission Path
biology_general/31